AXSM Axsome Therapeutics Inc.

55.79
-3.04  -5%
Previous Close 58.83
Open 56.46
Price To Book 11.57
Market Cap 2,068,437,793
Shares 37,075,422
Volume 761,811
Short Ratio
Av. Daily Volume 877,010
Stock charts supplied by TradingView

NewsSee all news

  1. Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

    Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary endpoints, p=0.02, 0.035,

  2. Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer's Disease Agitation

    Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic AXS-05 and placebo arms fully enrolled with estimated completion rate of more than 90% Topline

  3. Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for 1Q 2020

  4. Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  5. Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    Axsome to host conference call and webcast on Thursday, March 12, 2020 at 8:00 AM Eastern Time NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data met primary endpoint - April 15, 2019.
AXS-05
Smoking cessation
Phase 2/3 top-line data due early 2Q 2020
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 data did not meet primary endpoint. Secondary endpoints met. Second Phase 3 trial to commence 3Q 2020.
AXS-05 STRIDE-1
Treatment resistant depression
NDA filing due 4Q 2020.
AXS-07 - MOMENTUM
Migraine
NDA filing due 4Q 2020.
AXS-05 -GEMINI
Major Depressive Disorder
Phase 3 trial to be initiated 2020.
AXS-12
Narcolepsy
Phase 3 data due early 2Q 2020.
AXS-07 - INTERCEPT
Migraine
Phase 3 trial met primary endpoints.
Esreboxetine (AXS-14)
Fibromyalgia

Latest News

  1. Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

    Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary endpoints, p=0.02, 0.035,

  2. Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer's Disease Agitation

    Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic AXS-05 and placebo arms fully enrolled with estimated completion rate of more than 90% Topline

  3. Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for 1Q 2020

  4. Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  5. Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    Axsome to host conference call and webcast on Thursday, March 12, 2020 at 8:00 AM Eastern Time NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical

  6. Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

    NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  7. Axsome Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  8. Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  9. Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

    Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome's pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary

  10. Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response

    Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated superiority to

  11. Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  12. Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  13. Axsome Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  14. Axsome Therapeutics Added to NASDAQ Biotechnology Index

    NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  15. Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

    Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically significant improvement at

  16. Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

    Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS; p<0.001 on

  17. Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

    Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company

  18. Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient screening in

  19. Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

    Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more likely to prescribe AXS-07 over current and other emerging

  20. Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy

    NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  21. Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference

      GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD on track for readout of topline results in 4Q 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for readout of topline results in 4Q 2019 MOMENTUM Phase 3

  22. Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society

    Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response to prior acute

  23. Innovative Drug-Delivery Systems Benefit Patients and Businesses

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often

  24. Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,